The Pharma Data

OCTOBER 28, 2020

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially preventing and treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Government 40

Government Long-Term Care Facilities Hospitals Therapies 40

The Pharma Data

JUNE 25, 2021

AstraZeneca today announced results from the STORM CHASER trial assessing the safety and efficacy of AZD7442, a long-acting antibody (LAAB) combination, for the prevention of symptomatic COVID-19 in participants recently exposed to the SARS-CoV-2 virus. The PROVENT trial will give us more clarity in this patient population.

Trials 52

Trials Virus Long-Term Care Facilities Government 52

The Pharma Data

APRIL 16, 2021

1.429 California strain that currently accounts for 50 percent of the virus in California and over 10 percent across a number of additional states. However, sites of care should not dispose of bamlanivimab supply; instead, they should order etesevimab to pair with it. All sites in the U.S. In the U.S.,

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

NOVEMBER 9, 2020

. “The BLAZE-1 data show bamlanivimab, when given early in the disease course, may help patients clear the virus and reduce COVID-related hospitalizations, supporting our belief that neutralizing antibodies can be an important therapeutic option for patients fighting this virus,” said Daniel Skovronsky, M.D.,

Treatment 52

Treatment FDA Hospitals Long-Term Care Facilities 52

The Pharma Data

JANUARY 24, 2021

Gritstone Oncology , based in Emeryville, California, announced that it is advancing development of its own second-generation vaccine against COVID-19. Transgene and BioInvent received approval from France’s national regulatory agency to begin a Phase I/IIa trial of Vaccinia virus BT-001 in solid tumors. Read on to see.

Long-Term Care Facilities 52

Long-Term Care Facilities Trials Virus Clinical Trials 52

The Pharma Data

MARCH 5, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab for the prevention of COVID-19 in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Treatment 40

Treatment Hospitals Long-Term Care Facilities Therapies 40

The Pharma Data

MAY 4, 2021

. “ Lilly ‘s action provides both important new options and potential resources for countries’ health and regulatory leaders to consider for the care of COVID-19 patients, and Direct Relief will of course move with urgency upon receiving any such requests.” Ricks , Lilly chairman and CEO.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

JANUARY 26, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987) is also ongoing.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

MARCH 11, 2021

It is designed to block viral attachment and entry into human cells, thus neutralizing the virus, potentially treating COVID-19. A Phase 3 study of bamlanivimab alone or bamlanivimab and etesevimab together in residents and staff at long-term care facilities (BLAZE-2, NCT04497987 ) is also ongoing.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40

The Pharma Data

DECEMBER 21, 2020

However, there are two vaccines that have been authorized in the U.S. Both vaccines require two doses, according to USA Today. Each of the vaccines targets the “spike protein” found on the surface of the virus that causes the illness. This typically allows the virus to attach itself to host cells and infect them.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Virus Clinical Trials 52

The Pharma Data

SEPTEMBER 6, 2021

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC). EMA will also be assessing data on booster doses.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Immune Response Virus 52

The Pharma Data

DECEMBER 4, 2020

And I think we’ll see a significant reduction” in the virus, Biden told CNN. Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. And it has stirred up a global debate about how to balance the dire need for a vaccine against the importance of looking for clear signs that a vaccine is safe.

Vaccine 52

Vaccine Long-Term Care Facilities Nurses Hospitals 52

The Pharma Data

DECEMBER 3, 2020

Though coronavirus cases have exploded recently, with new infections topping 1 million a week, a far smaller proportion of people who get the virus now are dying from it. ” Britain First to Approve Emergency Use of Pfizer’s COVID vaccine. But there are daunting obstacles to the vaccine’s delivery to the masses.

Hospitals 52

Hospitals Vaccine Long-Term Care Facilities Nurses 52

The Pharma Data

JANUARY 8, 2021

8, 2021 — President-elect Joe Biden plans to release nearly all available doses of COVID-19 vaccine when he takes office, reversing the Trump administration’s strategy of holding back half the supply to ensure second doses are available. We are in a race with this virus, so anything that speeds vaccination should be applauded.”

Vaccine 52

Vaccine Long-Term Care Facilities Hospitals FDA 52

The Pharma Data

DECEMBER 31, 2020

million doses of the approved Pfizer and Moderna COVID-19 vaccines had been distributed across the United States by Monday morning, just 2.1 That’s far too slow a pace, said one official charged with spearheading the vaccination of Americans. million vaccination tally — compiled by the U.S. . THURSDAY, Dec.

Vaccine 52

Vaccine Long-Term Care Facilities Virus Hospitals 52

The Pharma Data

DECEMBER 14, 2020

Below are newsworthy items compiled by HealthDay staff: No Early Vaccination of White House Officials. White House officials will no longer be among the first Americans to be vaccinated against COVID-19. I am not scheduled to take the vaccine, but look forward to doing so at the appropriate time.” © 2020 HealthDay.

Long-Term Care Facilities 52

Long-Term Care Facilities Vaccine Nurses Virus 52